|
Supplementary Figure
S2: Progression-free survival in patients who received etoposide and
non-etoposide (carboplatin-paclitaxel) as the standard chemotherapy
Aims: This
meta-analysis investigated the clinical benefits of chemo-immunotherapy in
extensive-stage small-cell lung cancer (ES-SCLC).
Methods/Results: Seven randomized controlled trials with a total of 2,862
patients were analyzed. Compared with chemotherapy alone, chemo-immunotherapy
provided a better progression-free survial (PFS) with a hazard ratio (HR) of
0.81; P<0.00001, and overall survival (OS) (HR, 0.82; P<0.0001). However,
the incidence of treatment related adverse effects (TRAEs) was significantly
increased. Subgroup analyses showed that a good performance status,
cisplatin-based chemotherapy, without brain metastases, and non-Asian
populations were associated with greater benefits in OS from
chemo-immunotherapy.
Conclusion: Chemo-immunotherapy demonstrated better PFS and OS compared to
chemotherapy alone as first-line treatment in ES-SCLC, but additional TRAEs
should be closely monitored.
|
